Aspira Women's Health (AWH) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 10, 2024
Document And Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Current Fiscal Year End Date	--12-31
Entity File Number	001-34810
Entity Registrant Name	Aspira Women’s Health Inc.
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	33-0595156
Entity Address, Address Line One	12117 Bee Caves Road
Entity Address, Address Line Two	Building III
Entity Address, Address Line Three	Suite 100
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78738
City Area Code	512
Local Phone Number	519-0400
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	AWH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		12,449,512
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Central Index Key	0000926617
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,413,000	$ 2,597,000
Accounts receivable, net of reserves of $2 and $15, as of March 31, 2024 and December 31, 2023, respectively	1,531,000	1,459,000
Prepaid expenses and other current assets	942,000	997,000
Inventories	236,000	227,000
Total current assets	6,122,000	5,280,000
Property and equipment, net	131,000	165,000
Right-of-use assets	620,000	528,000
Restricted cash	260,000	258,000
Other assets	31,000	31,000
Total assets	7,164,000	6,262,000
Current liabilities:
Accounts payable	1,643,000	1,261,000
Accrued liabilities	2,797,000	2,863,000
Current portion of long-term debt	249,000	166,000
Short-term debt	416,000	670,000
Current maturities of lease liabilities	188,000	159,000
Total current liabilities	5,293,000	5,119,000
Non-current liabilities:
Long-term debt	1,347,000	1,430,000
Non-current maturities of lease liabilities	487,000	427,000
Warrant liabilities	1,400,000	1,651,000
Total liabilities	8,527,000	8,627,000
Commitments and contingencies (Note 4)
Stockholders' deficit:
Common stock, par value $0.001 per share, 200,000,000 and 150,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 12,344,104 and 10,645,049 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	12,000	11,000
Additional paid-in capital	521,557,000	515,927,000
Accumulated deficit	(522,932,000)	(518,303,000)
Total stockholders' deficit	(1,363,000)	(2,365,000)
Total liabilities and stockholders' deficit	$ 7,164,000	$ 6,262,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Condensed Consolidated Balance Sheets [Abstract]
Accounts receivable, allowance	$ 2	$ 15
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	150,000,000
Common stock, shares issued	12,344,104	10,645,049
Common stock, shares outstanding	12,344,104	10,645,049

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Revenue	$ 2,153,000	$ 2,316,000
Cost of revenue:
Cost of revenue	939,000	1,130,000
Gross profit	1,214,000	1,186,000
Operating expenses:
Research and development	906,000	1,267,000
Sales and marketing	1,889,000	2,595,000
General and administrative	3,129,000	3,604,000
Total operating expenses	5,924,000	7,466,000
Loss from operations	(4,710,000)	(6,280,000)
Other income (expense), net:
Change in fair value of warrant liabilities	251,000	(24,000)
Interest (expense) income, net	(5,000)	26,000
Other expense, net	(165,000)	(300,000)
Total other income (expense), net	81,000	(298,000)
Net loss	$ (4,629,000)	$ (6,578,000)
Net loss per share - basic	$ (0.39)	$ (0.79)
Net loss per share - diluted	$ (0.39)	$ (0.79)
Weighted average common shares used to compute basic net loss per common share	11,846,075	8,313,091
Weighted average common shares used to compute diluted net loss per common share	11,846,075	8,313,091
Product [Member]
Revenue:
Revenue	$ 2,153,000	$ 2,315,000
Cost of revenue:
Cost of revenue	$ 939,000	1,130,000
Genetics [Member]
Revenue:
Revenue		$ 1,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Changes In Stockholders' (Deficit) Equity (unaudited) - USD ($)	Total	Equity Line of Credit Agreement [Member]	Registered Direct Offering [Member]	At the Market Offering Agreement [Member]	Common Stock [Member]	Common Stock [Member] Equity Line of Credit Agreement [Member]	Common Stock [Member] Registered Direct Offering [Member]	Common Stock [Member] At the Market Offering Agreement [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Equity Line of Credit Agreement [Member]	Additional Paid-In Capital [Member] Registered Direct Offering [Member]	Additional Paid-In Capital [Member] At the Market Offering Agreement [Member]	Accumulated Deficit [Member]
Balance, shares at Dec. 31, 2022					8,306,326
Balance at Dec. 31, 2022	$ 6,979,000				$ 8,000				$ 508,584,000				$ (501,613,000)
Net loss	(6,578,000)												(6,578,000)
Common stock issued, net of issuance costs, shares								23,217
Common stock issued, net of issuance costs				$ 30,000								$ 30,000
Stock-based compensation expense	396,000								396,000
Balance, shares at Mar. 31, 2023					8,329,543
Balance at Mar. 31, 2023	827,000				$ 8,000				509,010,000				(508,191,000)
Balance, shares at Dec. 31, 2023					10,645,049
Balance at Dec. 31, 2023	(2,365,000)				$ 11,000				515,927,000				(518,303,000)
Net loss	(4,629,000)												(4,629,000)
Common stock issued, net of issuance costs, shares						111,369	1,371,000
Common stock issued, net of issuance costs		$ 400,000	$ 4,869,000				$ 1,000			$ 400,000	$ 4,868,000
Warrant Exercise, shares					200,000
Common stock issued for vested restricted stock awards, shares					16,686
Stock-based compensation expense	362,000								362,000
Balance, shares at Mar. 31, 2024					12,344,104
Balance at Mar. 31, 2024	$ (1,363,000)				$ 12,000				$ 521,557,000				$ (522,932,000)

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Cash Flows (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (4,629,000)	$ (6,578,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash lease expense	(3,000)	1,000
Depreciation and amortization	29,000	70,000
Stock-based compensation expense	362,000	396,000
Change in fair value of warrant liabilities	(251,000)	24,000
Loss on impairment and disposal of property and equipment	25,000	1,000
Changes in operating assets and liabilities:
Accounts receivable	(72,000)	(309,000)
Prepaid expenses and other assets	55,000	323,000
Inventories	(9,000)	14,000
Accounts payable	382,000	(14,000)
Accrued liabilities	(66,000)	582,000
Other liabilities	(254,000)	(216,000)
Net cash used in operating activities	(4,431,000)	(5,706,000)
Cash flows from investing activities:
Purchase of property and equipment	(20,000)	(8,000)
Net cash used in investing activities	(20,000)	(8,000)
Cash flows from financing activities:
Principal repayment of DECD loan		(85,000)
Net cash provided by financing activities	5,269,000	(55,000)
Net decrease in cash, cash equivalents and restricted cash	818,000	(5,769,000)
Cash, cash equivalents and restricted cash, beginning of the period	2,855,000	13,557,000
Cash, cash equivalents and restricted cash, end of the period	3,673,000	7,788,000
Reconciliation to Consolidated Balance Sheet:
Cash and cash equivalents	3,413,000	7,535,000
Restricted cash	260,000	253,000
Unrestricted and restricted cash and cash equivalents	3,673,000	7,788,000
Supplemental disclosure of cash flow information:
Cash paid for interest	6,000	18,000
Supplemental disclosure of noncash investing and financing activities:
Net increase in right-of-use assets	169,000
At the Market Offering [Member]
Cash flows from financing activities:
Proceeds from issuance of common stock		162,000
Payment of issuance costs		$ (132,000)
Equity Line of Credit [Member]
Cash flows from financing activities:
Proceeds from issuance of common stock	400,000
Registered Direct Offering [Member]
Cash flows from financing activities:
Proceeds from issuance of common stock	5,563,000
Payment of issuance costs	$ (694,000)

Organization, Basis Of Presenta

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies	3 Months Ended
	Mar. 31, 2024
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies	1. ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Organization Aspira Women’s Health Inc. (“Aspira” and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services: (1) the Ova1Plus workflow, which uses Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Ova1 is a qualitative serum test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy. Overa is a second-generation biomarker test intended to maintain Ova1’s high sensitivity while improving specificity. The Ova1 workflow leverages the strengths of Ova1’s (MIA) sensitivity and Overa’s (MIAG2G) specificity to reduce incorrectly elevated results; and (2) OvaWatch, a Laboratory Developed Test (“LDT”) intended in the clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. Collectively, these tests are referred to and marketed as OvaSuite. For the three months ended March 31, 2024 and 2023, the Company’s product and related revenue was limited to the products described above, as well as residual revenue from Aspira GenetiX, which was discontinued in the third quarter of 2022. The Company’s products are distributed through its own national sales force, including field sales, inside sales and a contracted sales team, through its proprietary decentralized testing platform and cloud service marketed as Aspira Synergy, and through marketing and distribution agreements with BioReference Health, LLC and ARUP Laboratories. Overa is currently not offered commercially except as a reflex test performed as part of the Ova1Plus workflow . Going Concern and Liquidity As of March 31, 2024, the Company had approximately $ 3,413,000 of cash and cash equivalents (excluding restricted cash of $ 260,000 ), an accumulated deficit of approximately $ 522,932,000 , and working capital of approximately $ 829,000 . For the three months ended March 31, 2024, the Company incurred a net loss of $ 4,629,000 , and used cash in operations of $ 4,431,000 . The Company has incurred significant net losses and negative cash flows from operations since inception. The Company also expects to continue to incur a net loss and negative cash flows from operations for the remainder of 2024. In order to fund operations, meet its capital requirements or satisfy the anticipated obligations as they become due, the Company expects to take further action to protect its liquidity position, which include, but are not limited to: • Raising capital through equity or debt offerings either in the public markets or via private placement offering, to the extent that the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. However, no assurance can be given that capital will be available on acceptable terms, or at all; • Securing debt, however, no assurance can be given that debt will be available on acceptable terms or at all; • Reducing executive bonuses or replacing cash compensation with equity grants; • Reducing professional services and consulting fees and eliminating non-critical projects; • Reducing travel and entertainment expenses; and • Reducing eliminating or deferring discretionary marketing programs. The Company also has outstanding warrants to purchase shares of its common stock that may be exercised although there can be no assurance that the warrants will be exercised. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Management expects cash from product sales and licensing to be the Company’s only material, recurring source of cash in 2024. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these consolidated interim financial statements are filed. The unaudited condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The consolidated balance sheet at December 31, 2023 included in this report has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, filed with the SEC on April 1, 2024. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results. Significant Accounting Policies Revenue Recognition Product Revenue – OvaSuite : The Company recognizes product revenue in accordance with the provisions of Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). Product revenue is recognized upon completion of the OvaSuite test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The effect of any change made to an estimated input component and, therefore revenue recognized, would be recorded as a change in estimate at the time of the change. The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer ( i.e ., Medicare, patient pay, other third-party payer, etc. ) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the period ended March 31, 2024, there were $ 8,000 of adjustments to estimates of variable consideration to derecognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the three months ended March 31, 2024. The Company has discontinued providing Aspira GenetiX, including genetics carrier screening, on the Aspira Synergy platform, effective September 30, 2022. Accounts Receivable: Virtually all accounts receivable are derived from sales made to customers located in North America. The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The Company maintains an allowance for credit losses based upon the expected collectability of accounts receivable, including the historical collection cycle. Amounts are written off against the allowances for credit losses when the Company determines that a customer account is not collectable. The Company believes its exposure to concentrations of credit risk is limited due to the diversity of its payer base. Warrants: The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own stock and whether the events where holders of the warrants could potentially require net cash settlement are within the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital at the time of issuance and are not remeasured. Warrants that do not meet the required criteria for equity classification are classified as liabilities. The Company adjusts such warrants to fair value at each reporting period until the warrants are exercised or expire. Any change in fair value is recognized in the Company’s statement of operations. Recent Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This update was issued to assist in simplifying the accounting for convertible instruments. This ASU is scheduled to be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted the new standard on January 1, 2024 . The adoption of this standard did not have a material impact on its consolidated results of operations, financial position, or cash flows. In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”) to clarify guidance in Topic 820 on the fair value measurement of an equity security that is subject to a contractual sale restriction and also requires specific disclosures related to an equity security. ASU 2022-03 is scheduled to be effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect a material impact as a result of this standard on its results of operations, financial position, or cash flows. In October 2023, the FASB issued ASU No. 2023-06, D isclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (“ASU 2023-06”). The amendments in this ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC topics by aligning them with the SEC’s regulations. ASU 2023-06 will become effective for each amendment on the effective date of the SEC's corresponding disclosure rule changes. The Company does not expect ASU 2023-06 will have a material impact on its results of operations, financial position, or cash flows. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This ASU requires disclosure of significant segment expenses that are regularly provided to the Company’s Chief Operating Decision Maker (“CODM”) and included within the reported measure of a segment’s profit or loss, requires interim disclosures about a reportable segment’s profit or loss and assets that are currently required annually, requires disclosure of the position and title of the CODM, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, and contains other disclosure requirements. ASU 2023-07 is scheduled to be effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on its consolidated results of operations, financial position, or cash flows.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Fair Value Measurements [Abstract]
Fair Value Measurements	2. FAIR VALUE MEASUREMENTS Fair Value of Financial Instruments Financial instruments of the Company consist primarily of cash and cash equivalents, restricted cash accounts, receivable, and accounts payable, and warrant liability. These items are considered Level 1 due to their short-term nature and their market interest rates. Warrant liability is considered Level 2 and is recorded at fair value at the end of each reporting period. Debt is considered Level 3, which the Company does not record at fair value. The Company records warrants in connection with a public offering in 2022 (the “2022 Warrants”) as a liability. As discussed in Note 6 to the unaudited condensed consolidated financial statements, in connection with a registered direct offering in 2024, the Company amended certain of the 2022 Warrants to purchase up to an aggregate of 366,664 shares (the “Modified Warrants”). The terms of the remaining 433,321 of the 2022 Warrants were unchanged (the “Unmodified Warrants”). The fair values of the Warrants as of March 31, 2024 and December 31, 2023 were approximately $ 1,400,000 and $ 1,651,000 , respectively. The fair value of the 2022 Warrants was estimated using Black-Scholes pricing model based on the following assumptions: March 31, 2024 December 31, 2023 Unmodified Modified Dividend yield — % — % — % Volatility 104.9 % 101.7 % 105.1 % Risk-free interest rate 4.31 % 4.21 % 3.93 % Expected lives (years) 3.39 4.83 3.64 Weighted average fair value $ 1.329 $ 2.247 $ 2.064 The 2022 Warrants were deemed to be derivative instruments due to certain contingent put features. The fair value of the 2022 Warrants was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the 2022 Warrants issued, including a fixed term and exercise price. The fair value of the Warrants was affected by changes in inputs to the Black-Scholes option pricing model including the Company’s stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. This model uses Level 2 inputs, including stock price volatility, in the fair value hierarchy established by ASC 820, Fair Value Measurement. The 2022 Warrants are classified as a long-term liability on the Company’s balance sheet. The carrying value of the Company’s insurance promissory note approximates fair value as of March 31, 2024 and December 31, 2023, due to the short-term nature of the insurance note and is classified as Level 2 within the fair value hierarchy. The DECD loan is classified within Level 3 of the fair value hierarchy. The following table presents the carrying value and fair value of the DECD loan. The fair value of the DECD loan is estimated based on discounted cash flows using the prevailing market interest rates. March 31, December 31, 2024 2023 (in thousands) Fair Value Hierarchy Carrying Value Fair Value Carrying Value Fair Value DECD loan Level 3 $ 1,604 $ 1,287 $ 1,604 $ 1,255

Prepaid And Other Current Asset

Prepaid And Other Current Assets	3 Months Ended
	Mar. 31, 2024
Prepaid And Other Current Assets [Abstract]
Prepaid And Other Current Assets	3. PREPAID AND OTHER CURRENT ASSETS Prepaid and other current assets at March 31, 2024 and December 31, 2023 consist of the following: March 31, December 31, (in thousands) 2024 2023 Prepaid insurance $ 479 $ 684 Software licenses 173 103 Subscriptions 128 26 Other 162 184 Total prepaid and other current assets $ 942 $ 997

Commitments And Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments And Contingencies [Abstract]
Commitments And Contingencies	4. COMMITMENTS AND CONTINGENCIES Loan Agreement On March 22, 2016, the Company entered into a loan agreement (as amended, the “DECD Loan Agreement”) with the State of Connecticut Department of Economic and Community Development (the “DECD”), pursuant to which the Company may borrow up to $ 4,000,000 from the DECD. The loan bears interest at a fixed rate of 2.0 % per annum and requires equal monthly payments of principal and interest until maturity, which occurs on January 1, 2032 . As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender. The loan may be prepaid at any time without premium or penalty. An initial disbursement of $ 2,000,000 was made to the Company on April 15, 2016 under the DECD Loan Agreement. On December 3, 2020, the Company received a disbursement of the remaining $ 2,000,000 under the DECD Loan Agreement, as the Company had achieved the target employment milestone necessary to receive an additional $ 1,000,000 under the DECD Loan Agreement and the DECD determined to fund the remaining $ 1,000,000 under the DECD Loan Agreement after concluding that the required revenue target would likely have been achieved in the first quarter of 2020 in the absence of the impacts of COVID-19. Under the terms of the DECD Loan Agreement, the Company was eligible for forgiveness of up to $ 1,500,000 of the principal amount of the loan if it was able to achieve certain job creation and retention milestones by December 31, 2022. On June 26, 2023, the Company was notified by the DECD that the Company satisfied all job creation and retention requirements under the loan agreement to receive forgiveness of $ 1,000,000 . During the year ended December 31, 2023, the Company recorded the $ 1,000,000 as other income in the statement of operations. If the Company fails to maintain its Connecticut operations through March 22, 2026, the DECD may require early repayment of a portion or all of the remaining amount of the loan plus a penalty of 5 % of the total funded loan. On June 6, 2023, the Company was granted a deferral of interest and principal payments on a portion of the remaining outstanding balances through December 1, 2023. On January 30, 2024, the Company was granted an additional deferral of interest and principal payments on a portion of the remaining outstanding balances through June 1, 2024. The Company determined the loan deferrals met the definition of a troubled debt restructuring under ASC 470-60, Troubled Debt Restructurings by Debtors , as the Company was experiencing financial difficulties and the lenders granted a concession. The future undiscounted cash flows of the DECD loan after the loan deferrals exceeded the carrying value of the DECD loan prior to the loan deferrals. As such no gain was recognized as a result of the deferrals. Long-term debt consisted of the following: March 31, December 31, 2024 2023 (in thousands) DECD loan, net of issuance costs $ 1,596 $ 1,596 Less: Current portion, net of issuance costs ( 249 ) ( 166 ) Total long-term debt, net of issuance costs $ 1,347 $ 1,430 As of March 31, 2024, the annual amounts of future minimum principal payments due under the Company’s contractual obligation are shown in the table below. Unamortized debt issuance costs for the DECD loan were $ 8,000 for both the three months ended March 31, 2024 and December 31, 2023, respectively. Payments Due by Period (in thousands) Total 2024 2025 2026 2027 2028 Thereafter DECD Loan $ 1,604 $ 170 $ 335 $ 342 $ 215 $ 129 $ 413 Total $ 1,604 $ 170 $ 335 $ 342 $ 215 $ 129 $ 413 Insurance Notes During 2023, the Company entered into an insurance promissory note for the payment of insurance premiums at an interest rate of 7.79 %, with an aggregate principal amount outstanding of approximately $ 416,000 and $ 670,000 as of March 31, 2024 and December 31, 2023, respectively. Interest paid for the promissory note was $ 6,000 for each of the quarters ended March 31, 2024 and 2023. The amount outstanding in 2024 could be substantially offset by the cancellation of the related insurance coverage which is classified in prepaid insurance. This note is payable in nine monthly installments with a maturity date of October 1, 2024 and has no financial or operational covenants. Operating Leases The Company leases facilities to support its business. The Company’s principal facility, including the Clinical Laboratory Improvements Amendments of 1988 (“CLIA”) laboratory used by Aspira Labs, Inc., is located in Austin, Texas, and administrative offices are located in Trumbull, Connecticut and Palo Alto, California. In October 2015, the Company entered into a lease agreement for a facility in Trumbull, Connecticut, which was renewed in September 2020. In May 2023, the Company entered into an agreement with the owner of its Trumbull, Connecticut offices to move to a more economical location in Shelton, Connecticut and replacing the Trumbull, Connecticut office lease. The new lease term is for five years , and its commencement date was October 1, 2023. Beginning on October 1, 2023, the fixed lease payment was reduced from approximately $ 8,900 per month to $ 5,000 per month for the first year, and to $ 5,383 per month for years two through four and $ 5,768 per month for the fifth year. Continuation of the lease would be on a month-to-month basis. In January 2023, the Company entered into a new sublease agreement for an administrative facility in Palo Alto, California. The Company’s sublease term commenced in April 2023 and terminates on May 31, 2024 , with no option for renewal with the sublessor . The fixed lease payment was initially approximately $ 9,000 per month and increased to approximately $ 10,000 per month beginning in January 2024. In July 2023, the Company extended the Austin, Texas lease for an additional 37 months. The Company’s renewed lease expires on February 28, 2027 , with the option to extend the lease for an additional three years . Prior to the renewal, the Company’s Texas lease had a term of 12 months, and the Company has elected the policy of not recording leases on the balance sheet when the leases have terms of 12 months or less. Through June 30, 2023, the Company recognized the lease payments in profit and loss on a straight-line basis over the term of the lease, and variable lease payments in the period in which the obligation for the payments was incurred. Variable lease costs represent the Company’s share of the landlord’s operating expenses. Beginning in the third quarter of 2023, the Company added the extended Austin, Texas lease to its balance sheet as a right-of-use asset. Beginning February 1, 2024, the fixed lease payment were reduced from approximately $ 9,490 per month to approximately $ 7,100 per month for the first year (except for August 2024, which will be $ 0 ), and will be approximately $ 8,600 per month for the second year, approximately $ 8,900 per month for the third year and approximately $ 9,100 for the final month. The Company is not reasonably certain that it will exercise the three-year renewal option beginning on March 1, 2027. Effective October 31, 2023, the Company entered into a new lease agreement for freezer storage for its samples. The lease term is for 36 months with a twelve-month automatic renewal provision . The company leases 6 freezers at a total of $ 5,200 per month. The Company added the lease to its balance sheet as a right-of-use asset in the first quarter of 2024. The expense associated with these operating leases for the three months ended March 31, 2024 and 2023 is shown in the table below (in thousands). Three Months Ended Lease Cost Classification 2024 2023 Operating rent expense Cost of revenue $ 41 $ 24 Research and development 17 6 Sales and marketing 1 2 General and administrative 10 21 Variable rent expense Cost of revenue 5 15 Research and development - 3 Sales and marketing 2 2 General and administrative 9 21 Based on the Company’s leases as of March 31, 2024, the table below sets forth the approximate future lease payments related to operating leases with initial terms of one year or more (in thousands). Year Payments 2024 $ 172 2025 229 2026 223 2027 84 2028 52 Total Operating Lease Payments 760 Less: Imputed Interest ( 85 ) Present Value of Lease Liabilities 675 Less: Operating Lease Liability, current portion ( 188 ) Operating Lease Liability, non-current portion $ 487 Weighted-average lease term and discount rate were as follows. Three Months Ended March 31, 2024 2023 Cash paid for amounts included in measurement of lease liabilities: Operating cash outflows relating to operating leases $ 117 $ 111 Weighted-average remaining lease term (in years) 3.3 3.2 Weighted-average discount rate 7.28 % 9.29 % Non-cancellable Royalty Obligations The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine under which the Company licenses certain of its intellectual property directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human disease. Under the terms of the amended research collaboration agreement, Aspira is required to pay the greater of 4 % royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $ 57,500 . Royalty expense for the three months ended March 31, 2024 and 2023 totaled $ 72,000 and $ 90,000 , respectively, and are recorded in cost of revenue in the unaudited condensed consolidated statements of operations. Business Agreements On August 8, 2022, the Company entered into a sponsored research agreement with Harvard’s Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz (the “Dana-Farber, Brigham, Lodz Research Agreement”), for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating microRNAs and proteins. The Dana-Farber, Brigham, Lodz Research Agreement requires payments to be made upon the achievement of certain milestones. Under the terms of and as further described in the Dana-Farber, Brigham, Lodz Research Agreement, payments of approximately $ 1,252,000 have or will become due from the Company to the counterparties upon successful completion of certain deliverables as follows: 68 % was paid in 2022, 15 % was paid in 2023, and the remaining 17 % will become payable upon completion of certain deliverables estimated to occur in the first half of 2024. During the three months ended March 31, 2024 and 2023, approximately $ 34,000 and $ 23,000 has been recorded, respectively, as research and development expense in the unaudited condensed consolidated financial statement of operations for the project. From the inception of the Dana-Farber, Brigham, Lodz Research Agreement through March 31, 2024, research and development expenses in the cumulative amount of $ 1,117,000 have been recorded. On March 20, 2023, the Company entered into a licensing agreement (“Dana-Farber, Brigham, Lodz License Agreement”) with Harvard’s Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz under which the Company will license certain of its intellectual property to be used in the Company’s OvaSuite product portfolio. Under the Dana-Farber, Brigham, Lodz License Agreement, the Company paid an initial license fee of $ 75,000 and pays an annual license maintenance fee of $ 50,000 on each anniversary of the date of the Dana-Farber, Brigham, Lodz License Agreement. The Company recorded $ 50,000 in annual license maintenance fees over the twelve month period ended March 20, 2024. The Dana-Farber, Brigham, Lodz License Agreement also requires non-refundable royalty payments of up to $ 1,350,000 based on certain regulatory approvals and commercialization milestones and further royalty payments based on the net sales of the Company’s products included under the Dana-Farber, Brigham, Lodz License Agreement. No milestones have been reached as of March 31, 2024. Contingent Liabilities From time to time, the Company is involved in legal proceedings and regulatory proceedings arising from operations. The Company establishes reserves for specific liabilities in connection with legal actions that management deems to be probable and estimable. The Company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the Company’s financial position or results of operations.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2024
Accrued Liabilities [Abstract]
Accrued Liabilities	5. ACCRUED LIABILITIES The following table describes the principal components of accrued liabilities on the Company’s unaudited condensed consolidated balance sheet as of March 31, 2024 and December 31, 2023. March 31, December 31, (in thousands) 2024 2023 Payroll and benefits related expenses $ 1,328 $ 1,189 Collaboration and research agreements expenses 99 217 Professional services 911 951 Other accrued liabilities 459 506 Total accrued liabilities $ 2,797 $ 2,863

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Mar. 31, 2024
Stockholders' (Deficit) Equity [Abstract]
Stockholders' (Deficit) Equity	6. STOCKHOLDERS’ DEFICIT 2024 Registered Direct Offering On January 24, 2024, the Company entered into a securities purchase agreement (the “2024 Direct Offering Agreement”), with several investors relating to the issuance and sale of 1,371,000 shares of its common stock, par value $ 0.001 per share, and pre-funded warrants to purchase 200,000 shares of Common Stock (the “Pre-Funded Warrants”), in a registered direct offering, together with accompanying warrants to purchase 1,571,000 shares of Common Stock (the “Purchase Warrants”, and together with the Pre-Funded Warrants, the “Warrants”) in a concurrent private placement (the “Concurrent Private Offering” and together with the registered direct offering, the “2024 Direct Offering”). Pursuant to the 2024 Direct Offering Agreement, the Company issued 1,368,600 shares of common stock to certain investors at an offering price of $ 3.50 per share, and 2,400 shares of common stock to its Chief Executive Officer, Nicole Sandford, at an offering price of $ 4.2555 per share, which was the consolidated closing bid price of the Company’s common stock on The Nasdaq Capital Market on January 24, 2024 of $ 4.13 per share plus $ 0.125 per Purchase Warrant. The purchase price of each Pre-Funded Warrant is equal to the combined purchase price at which a share of Common Stock and the accompanying Purchase Warrant is sold in this 2024 Direct Offering, minus $ 0.0001 . The gross proceeds to the Company from the 2024 Direct Offering were approximately $ 5,563,000 , before deducting placement agent fees and other estimated expenses of $ 694,000 payable by the Company. The 2024 Direct Offering closed on January 26, 2024. The Pre-Funded Warrants were exercisable at any time after the date of issuance and had an exercise price of $ 0.0001 per share. A holder of Pre-Funded Warrants could not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99 % of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage to a percentage not in excess of 9.99 % by providing at least 61 days’ prior notice to the Company. All of the Pre-Funded Warrants were exercised on February 6, 2024 for gross proceeds of $ 20 . The Purchase Warrants have an exercise price of $ 4.13 per share and will be exercisable beginning six months after issuance and will expire 5 years from the initial exercise date. The Company engaged AGP to act as sole placement agent in the 2024 Direct Offering. The Company paid the placement agent a cash fee equal to 7.0 % of the aggregate gross proceeds generated from the 2024 Direct Offering, except that, with respect to proceeds raised in this 2024 Direct Offering from certain designated persons, AGP’s cash fee is reduced to 3.5 % of such proceeds, and to reimburse certain fees and expenses of the placement agent in connection with the 2024 Direct Offering. The Company also reimbursed the placement agent for its accountable offering-related legal expenses of $ 75,000 and a non-accountable expense allowance of $ 30,000 . Costs related to the 2024 Direct Offering were recorded as an offset to additional paid-in capital on the Company's balance sheet as of March 31, 2024. The Company evaluated the Pre-Funded Warrants and the Purchase Warrants and concluded that they met the criteria to be classified as equity within additional paid-in-capital. The Pre-Funded Warrants are equity classified because they (1) are freestanding financial instruments that are legally detachable and separately exercisable from the common stock, (2) are immediately exercisable, (3) do not embody an obligation for the Company to repurchase its shares, (4) permit the holder to receive a fixed number of shares of common stock upon exercise, (5) are indexed to the Company's common stock and (6) meet the equity classification criteria. The Purchase Warrants are equity classified because they (1) are freestanding financial instruments that are legally detachable and separately exercisable from the common stock, (2) do not embody an obligation for the Company to repurchase its shares, (3) permit the holder to receive a fixed number of shares of common stock upon exercise, (4) are indexed to the Company's common stock and (5) meet the equity classification criteria. Effective upon the closing of the 2024 Direct Offering, the Company also amended certain existing warrants (the “2022 Warrants” ), see Note 7 in our Annual Report on Form 10-K for the fiscal year-ended December 31, 2023, to purchase up to an aggregate of 366,664 shares at an exercise price of $ 13.20 per share and a termination date of August 25, 2027, so that the amended 2022 Warrants have a reduced exercise price of $ 4.13 per share and a new termination date of January 26, 2029. The other terms of the amended 2022 Warrants remain unchanged. The Company performed an analysis of the fair value of the 2022 Warrants immediately before and after the modification and the increase in fair value of the 2022 Warrants of $ 490 thousand was recorded as a change in fair value of warrant liabilities in the unaudited condensed statement of operations. Approximately $ 106,000 of the costs related to the 2024 Direct Offering were allocated to the 2022 Warrants and were recorded as other expense in the unaudited condensed statement of operations. 2023 Registered Direct Offering On July 20, 2023, the Company entered into a securities purchase agreement (the “Direct Offering Agreement”), with several investors relating to the issuance and sale of 1,694,820 shares of its common stock, par value $ 0.001 per share (the “Direct Offering”). Pursuant to the Direct Offering Agreement, the Company issued 1,650,473 shares of common stock to certain investors at an offering price of $ 2.75 per share, and 44,347 shares of common stock to its directors and executive officers at an offering price of $ 3.98 per share, which was the consolidated closing bid price of the Company’s common stock on The Nasdaq Capital Market on July 19, 2023. The aggregate gross proceeds to the Company from the Direct Offering were approximately $ 4.7 million, before deducting placement agent fees and other estimated expenses of $ 597,000 payable by the Company. The Company engaged Alliance Global Partners to act as sole placement agent in the Direct Offering. The Company paid the placement agent a cash fee equal to 7.0 % of the aggregate gross proceeds generated from the Direct Offering, except that, with respect to proceeds from the sale of 182,447 shares of common stock to certain investors, including directors and executive officers of the Company, the placement agent’s cash fee was 3.5 %. The Company also reimbursed the placement agent for its accountable offering-related legal expenses of $ 75,000 and a non-accountable expense allowance of $ 30,000 . 2023 At the Market Offering On February 10, 2023, the Company entered into a Controlled Equity Offering Sales Agreement, (the “Cantor Sales Agreement”), with Cantor Fitzgerald & Co., (“Cantor”), as agent, pursuant to which it may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $ 0.001 per share, having an aggregate offering price of up to $ 12.5 million, (the “Placement Shares”). The Placement Shares were issued and sold pursuant to the Company’s effective registration statement on Form S-3 (Registration Statement No. 333-252267), as previously filed with, and declared effective by, the SEC. The Company filed a prospectus supplement, dated February 10, 2023, with the SEC in connection with the offer and sale of the Placement Shares. In connection with the Direct Offering on July 24, 2023, the Company delivered written notice to Cantor on July 19, 2023 that it was suspending the prospectus supplement, dated February 10, 2023, related to the Company’s common stock issuable under the Cantor Sales Agreement. The Company will not make any sales of common stock pursuant to the Cantor Sales Agreement unless and until a new prospectus supplement is filed with the SEC. The Cantor Sales Agreement remains in full force and effect during the suspension. During the three months ended March 31, 2024, the Company sold 0 Placement Shares and recorded no transaction related offering costs. Over the life of the Cantor Sales Agreement, the Company sold 35,552 shares of the Placement Shares for gross proceeds of approximately $ 211,000 . The Company has recorded $ 134,000 as an offset to additional paid-in capital representing transaction-related offering costs of the Placement Shares over the life of the Cantor Sales Agreement. 2023 Equity Line of Credit On March 28, 2023, the Company entered into a purchase agreement (the “LPC Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”) and a registration rights agreement (the “LPC Registration Rights Agreement”), pursuant to which the Company has the right, in its sole discretion, to sell to Lincoln Park shares of the Company’s common stock, par value $ 0.001 per share (the “Common Stock”), having an aggregate value of up to $ 10,000,000 (the “Purchase Shares”), subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of Purchase Shares to Lincoln Park pursuant to the LPC Purchase Agreement. Under the LPC Purchase Agreement, on any business day after March 28, 2023 selected by the Company over the 36-month term of the LPC Purchase Agreement (each, a “Purchase Date”), the Company may direct Lincoln Park to purchase up to 6,667 shares of Common Stock on such Purchase Date (a “Regular Purchase”); provided, however, that (i) a Regular Purchase may be increased to up to 13,333 shares, if the closing sale price per share of the Common Stock on The Nasdaq Capital Market is not below $ 7.50 on the applicable Purchase Date; (ii) a Regular Purchase may be increased to up to 16,666 shares, if the closing sale price per share of the Common Stock on The Nasdaq Capital Market is not below $ 11.25 on the applicable Purchase Date; and (iii) a Regular Purchase may be increased to up to 20,000 shares, if the closing sale price per share of the Common Stock on The Nasdaq Capital Market is not below $ 15.00 on the applicable Purchase Date. In any case, Lincoln Park’s maximum obligation under any single Regular Purchase will not exceed $ 1,000,000 . The above-referenced share amount limitations and closing sale price thresholds are subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as provided in the LPC Purchase Agreement. The purchase price per share for each such Regular Purchase will be equal to the lesser of: 1. the lowest sale price for the Common Stock on The Nasdaq Capital Market on the date of sale; and 2. the average of the three lowest closing sale prices for the Common Stock on The Nasdaq Capital Market during the 10 consecutive business days ending on the business day immediately preceding the purchase date. The Company also has the right to direct Lincoln Park, on any business day on which the Company has properly submitted a Regular Purchase notice for the maximum amount the Company is then permitted to sell to Lincoln Park in such Regular Purchase, to purchase an additional amount of the Common Stock (an “Accelerated Purchase”) of additional shares based on criteria established in the LPC Purchase Agreement. An Accelerated Purchase, which is at the Company’s sole discretion, may be subject to additional requirements and discounts if certain conditions are met as defined in the LPC Purchase Agreement. The issuance of the Purchase Shares had been previously registered pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-252267) (the “Old Registration Statement”), and the related base prospectus included in the Registration Statement, as supplemented by a prospectus supplement filed on March 28, 2023, that has expired. On April 22, 2024, the Company has filed a registration statement on Form S-3 (File No. 333-278867) (the “Registration Statement”), and the related base prospectus included in the Registration Statement, that was declared effective by the SEC on April 25, 2024. The Company sold 472,312 shares of Common Stock under the LPC Purchase Agreem ent for gross proceeds of approximately $ 1,578,000 under the Old Registration Statement. In addition, 47,733 shares of Common Stock were issued to Lincoln Park as consideration for entering into the LPC Purchase Agreement. As of April 25, 2024, up to $ 8,422,000 of shares of Common Stock could be sold to Lincoln Park under the LPC Purchase Agreement, subject to the terms of the LPC Purchase Agreement. During the three months ended March 31, 2024, the Company sold 111,369 shares under the LPC Purchase Agreement for gross proceeds of approximately $ 400,000 . Over the life of the LPC Purchase Agreement through March 31, 2024, the Company sold 472,312 shares for gross proceeds of approximately $ 1,578,000 . The Company incurred approximately $ 326,000 of costs related to the execution of the LPC Purchase Agreement, all of which are reflected in the unaudited condensed consolidated financial statements. Of the total costs incurred, approximately $ 258,000 was paid in common stock to Lincoln Park for a commitment fee and $ 30,000 was accrued for Lincoln Park expenses. These transaction costs were included in other expense in the statement of operations for the year ended December 31, 2023. Approximately $ 38,000 was incurred for legal fees during the year ended December 31, 2023, and were included in general and administrative expenses on the statement of operations. During the three months ended March 31, 2024 and 2023, the Company paid legal fees of $ 40,000 and none , respectively. Subsequent to March 31, 2024, the Company sold 100,408 shares under the LPC Purchase Agreement for gross proceeds of approximately $ 300,000 , as of May 10, 2024. 2010 Stock Incentive Plan The Company’s employees, directors, and consultants were eligible to receive awards under the Vermillion, Inc. Second Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”), which was replaced by the 2019 Plan (as defined below) with respect to future equity grants. As of March 31, 2024, there were no shares of the Company’s common stock available for future grants under the 2010 Plan. The following table summarizes stock option activity for the 2010 Plan during the three months ended March 31, 2024. Options outstanding at December 31, 2023 245,154 Options forfeited or expired ( 33,965 ) Options outstanding at March 31, 2024 211,189 The weighted average exercise price of outstanding options under the 2010 Plan was $ 24.05 and the weighted average remaining life was 0.70 years. 2019 Stock Incentive Plan At the Company’s 2019 annual meeting of stockholders, the Company’s stockholders approved the Vermillion, Inc. 2019 Stock Incentive Plan, the name of which was subsequently changed to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan (the “2019 Plan”). The purposes of the 2019 Plan are (i) to align the interests of the Company’s stockholders and recipients of awards under the 2019 Plan by increasing the proprietary interest of such recipients in the Company’s growth and success; (ii) to advance the interests of the Company by attracting and retaining non-employee directors, officers, other employees, consultants, independent contractors and agents; and (iii) to motivate such persons to act in the long-term best interests of the Company and its stockholders. The 2019 Plan allows the Company to grant stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to participants. Subject to the terms and conditions of the 2019 Plan, the initial number of shares authorized for grants under the 2019 Plan is 699,485 . On May 9, 2023, the Company’s stockholders approved an increase of 333,333 shares to the number of shares available for issuance under the 2019 Plan. On May 13, 2024, the Company’s stockholders approved an increase of 1,000,000 shares in the number of shares available for issuance under the 2019 Plan for a total of 2,032,818 shares. To the extent an equity award granted under the 2019 Plan expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares of common stock subject to such award will become available for future grant under the 2019 Plan. As of March 31, 2024, 614,087 shares of Aspira common stock were subject to outstanding stock options, and 42,777 shares of Aspira common stock were subject to unreleased restricted stock awards and a total of 66,542 shares of Aspira common stock were reserved for future issuance under the 2019 Plan. The following table summarizes stock option activity for the 2019 Plan during the three months ended March 31, 2024. Options outstanding at December 31, 2023 514,768 Options granted 140,124 Options forfeited or expired ( 40,805 ) Options outstanding at March 31, 2024 614,087 The weighted average exercise price of outstanding options under the 2019 Plan was $ 11.77 and the weighted average remaining life was 1.92 years. The following table summarizes RSU activity for the 2019 Plan during the three months ended March 31, 2024. Options outstanding at December 31, 2023 59,463 RSUs vested and issued ( 16,686 ) Options outstanding at March 31, 2024 42,777 RSUs vested and unissued at March 31, 2024 22,777 Stock-Based Compensation During the three months ended March 31, 2024, the Company granted option awards under the 2019 Plan with a weighted average grant date fair value of $ 2.97 and a weighted average exercise price of $ 4.77 . Assumptions included in the fair value per share calculations were (i) expected terms of two to three years , (ii) two- to three-year treasury interest rates of 4.33 % to 4.56 % and (iii) market close prices ranging from $ 4.00 to $ 4.87 . The Company recorded $ 12,000 in forfeitures for the three months ended March 31, 2024. The allocation of non-cash stock-based compensation expense by functional area for the three months ended March 31, 2024 and 2023 was as follows. Three Months Ended March 31, (in thousands) 2024 2023 Cost of revenue $ 18 $ 17 Research and development 66 103 Sales and marketing 25 ( 15 ) General and administrative 253 291 Total $ 362 $ 396 As of March 31,2024, total unrecognized compensation cost related to unvested stock option awards was approximately $ 696,000 , and the related weighted average period over which it is expected to be recognized was 1.92 years. As of March 31,2024, there was $ 52,000 in unrecognized compensation costs related to restricted stock units, and the related weighted average period over which it is expected to be recognized is 0.25 years.

Loss Per Share

Loss Per Share	3 Months Ended
	Mar. 31, 2024
Loss Per Share [Abstract]
Loss Per Share	7. LOSS PER SHARE The Company calculates basic loss per share using the weighted average number of shares of Aspira common stock outstanding during the period. Because the Company is in a net loss position, diluted loss per share is calculated using the weighted average number of shares of Aspira common stock outstanding and excludes the anti-dilutive effects of 3,239,038 potential shares of Aspira common stock for the three months ended March 31, 2024 and 1,583,982 potential shares of Aspira common stock for the three months ended March 31, 2023, inclusive of 2,370,985 and 799,985 shares of Aspira common stock issuable upon the exercise of the warrants outstanding as of March 31, 2024 and 2023, respectively. Potential shares of Aspira common stock and warrants include incremental shares of Aspira common stock issuable upon the exercise of stock options and warrants and the vesting of unvested restricted stock units. Three Months Ended March 31, 2024 2023 Numerator: Net Loss $ ( 4,629 ) $ ( 6,578 ) Denominator: Shares used in computing net loss per share, basic and diluted 11,846,075 8,313,091 Net loss per share, basic and diluted $ ( 0.39 ) $ ( 0.79 )

Organization, Basis Of Presen_2

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Policy)	3 Months Ended
	Mar. 31, 2024
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization	Organization Aspira Women’s Health Inc. (“Aspira” and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services: (1) the Ova1Plus workflow, which uses Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Ova1 is a qualitative serum test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy. Overa is a second-generation biomarker test intended to maintain Ova1’s high sensitivity while improving specificity. The Ova1 workflow leverages the strengths of Ova1’s (MIA) sensitivity and Overa’s (MIAG2G) specificity to reduce incorrectly elevated results; and (2) OvaWatch, a Laboratory Developed Test (“LDT”) intended in the clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. Collectively, these tests are referred to and marketed as OvaSuite. For the three months ended March 31, 2024 and 2023, the Company’s product and related revenue was limited to the products described above, as well as residual revenue from Aspira GenetiX, which was discontinued in the third quarter of 2022. The Company’s products are distributed through its own national sales force, including field sales, inside sales and a contracted sales team, through its proprietary decentralized testing platform and cloud service marketed as Aspira Synergy, and through marketing and distribution agreements with BioReference Health, LLC and ARUP Laboratories. Overa is currently not offered commercially except as a reflex test performed as part of the Ova1Plus workflow .
Going Concern and Liquidity	Going Concern and Liquidity As of March 31, 2024, the Company had approximately $ 3,413,000 of cash and cash equivalents (excluding restricted cash of $ 260,000 ), an accumulated deficit of approximately $ 522,932,000 , and working capital of approximately $ 829,000 . For the three months ended March 31, 2024, the Company incurred a net loss of $ 4,629,000 , and used cash in operations of $ 4,431,000 . The Company has incurred significant net losses and negative cash flows from operations since inception. The Company also expects to continue to incur a net loss and negative cash flows from operations for the remainder of 2024. In order to fund operations, meet its capital requirements or satisfy the anticipated obligations as they become due, the Company expects to take further action to protect its liquidity position, which include, but are not limited to: • Raising capital through equity or debt offerings either in the public markets or via private placement offering, to the extent that the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. However, no assurance can be given that capital will be available on acceptable terms, or at all; • Securing debt, however, no assurance can be given that debt will be available on acceptable terms or at all; • Reducing executive bonuses or replacing cash compensation with equity grants; • Reducing professional services and consulting fees and eliminating non-critical projects; • Reducing travel and entertainment expenses; and • Reducing eliminating or deferring discretionary marketing programs. The Company also has outstanding warrants to purchase shares of its common stock that may be exercised although there can be no assurance that the warrants will be exercised. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Management expects cash from product sales and licensing to be the Company’s only material, recurring source of cash in 2024. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these consolidated interim financial statements are filed. The unaudited condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The consolidated balance sheet at December 31, 2023 included in this report has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, filed with the SEC on April 1, 2024. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results.
Revenue Recognition	Revenue Recognition Product Revenue – OvaSuite : The Company recognizes product revenue in accordance with the provisions of Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). Product revenue is recognized upon completion of the OvaSuite test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The effect of any change made to an estimated input component and, therefore revenue recognized, would be recorded as a change in estimate at the time of the change. The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer ( i.e ., Medicare, patient pay, other third-party payer, etc. ) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the period ended March 31, 2024, there were $ 8,000 of adjustments to estimates of variable consideration to derecognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the three months ended March 31, 2024. The Company has discontinued providing Aspira GenetiX, including genetics carrier screening, on the Aspira Synergy platform, effective September 30, 2022. Accounts Receivable: Virtually all accounts receivable are derived from sales made to customers located in North America. The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The Company maintains an allowance for credit losses based upon the expected collectability of accounts receivable, including the historical collection cycle. Amounts are written off against the allowances for credit losses when the Company determines that a customer account is not collectable. The Company believes its exposure to concentrations of credit risk is limited due to the diversity of its payer base. Warrants: The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own stock and whether the events where holders of the warrants could potentially require net cash settlement are within the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital at the time of issuance and are not remeasured. Warrants that do not meet the required criteria for equity classification are classified as liabilities. The Company adjusts such warrants to fair value at each reporting period until the warrants are exercised or expire. Any change in fair value is recognized in the Company’s statement of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This update was issued to assist in simplifying the accounting for convertible instruments. This ASU is scheduled to be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted the new standard on January 1, 2024 . The adoption of this standard did not have a material impact on its consolidated results of operations, financial position, or cash flows. In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”) to clarify guidance in Topic 820 on the fair value measurement of an equity security that is subject to a contractual sale restriction and also requires specific disclosures related to an equity security. ASU 2022-03 is scheduled to be effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect a material impact as a result of this standard on its results of operations, financial position, or cash flows. In October 2023, the FASB issued ASU No. 2023-06, D isclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (“ASU 2023-06”). The amendments in this ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC topics by aligning them with the SEC’s regulations. ASU 2023-06 will become effective for each amendment on the effective date of the SEC's corresponding disclosure rule changes. The Company does not expect ASU 2023-06 will have a material impact on its results of operations, financial position, or cash flows. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This ASU requires disclosure of significant segment expenses that are regularly provided to the Company’s Chief Operating Decision Maker (“CODM”) and included within the reported measure of a segment’s profit or loss, requires interim disclosures about a reportable segment’s profit or loss and assets that are currently required annually, requires disclosure of the position and title of the CODM, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, and contains other disclosure requirements. ASU 2023-07 is scheduled to be effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The adoption of this standard is not expected to have a material impact on its consolidated results of operations, financial position, or cash flows.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Measurements [Abstract]
Schedule Of Assumptions Used To Calculate Fair Value Of Warrants	March 31, 2024 December 31, 2023 Unmodified Modified Dividend yield — % — % — % Volatility 104.9 % 101.7 % 105.1 % Risk-free interest rate 4.31 % 4.21 % 3.93 % Expected lives (years) 3.39 4.83 3.64 Weighted average fair value $ 1.329 $ 2.247 $ 2.064
Carrying And Fair Value Of Loan Payable	March 31, December 31, 2024 2023 (in thousands) Fair Value Hierarchy Carrying Value Fair Value Carrying Value Fair Value DECD loan Level 3 $ 1,604 $ 1,287 $ 1,604 $ 1,255

Prepaid And Other Current Ass_2

Prepaid And Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Prepaid And Other Current Assets [Abstract]
Schedule Of Prepaid And Other Current Assets	Prepaid and other current assets at March 31, 2024 and December 31, 2023 consist of the following: March 31, December 31, (in thousands) 2024 2023 Prepaid insurance $ 479 $ 684 Software licenses 173 103 Subscriptions 128 26 Other 162 184 Total prepaid and other current assets $ 942 $ 997

Commitments And Contingencies (

Commitments And Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Commitments And Contingencies [Abstract]
Schedule Of Long-Term Debt	Long-term debt consisted of the following: March 31, December 31, 2024 2023 (in thousands) DECD loan, net of issuance costs $ 1,596 $ 1,596 Less: Current portion, net of issuance costs ( 249 ) ( 166 ) Total long-term debt, net of issuance costs $ 1,347 $ 1,430
Annual Amounts Of Future Minimum Principal Payments Due Under Certain Contractual Obligations	Payments Due by Period (in thousands) Total 2024 2025 2026 2027 2028 Thereafter DECD Loan $ 1,604 $ 170 $ 335 $ 342 $ 215 $ 129 $ 413 Total $ 1,604 $ 170 $ 335 $ 342 $ 215 $ 129 $ 413
Expense Associated With Operating Leases	The expense associated with these operating leases for the three months ended March 31, 2024 and 2023 is shown in the table below (in thousands). Three Months Ended Lease Cost Classification 2024 2023 Operating rent expense Cost of revenue $ 41 $ 24 Research and development 17 6 Sales and marketing 1 2 General and administrative 10 21 Variable rent expense Cost of revenue 5 15 Research and development - 3 Sales and marketing 2 2 General and administrative 9 21
Future Lease Payments Related To Operating Leases	Based on the Company’s leases as of March 31, 2024, the table below sets forth the approximate future lease payments related to operating leases with initial terms of one year or more (in thousands). Year Payments 2024 $ 172 2025 229 2026 223 2027 84 2028 52 Total Operating Lease Payments 760 Less: Imputed Interest ( 85 ) Present Value of Lease Liabilities 675 Less: Operating Lease Liability, current portion ( 188 ) Operating Lease Liability, non-current portion $ 487
Summary Of Weighted-Average Lease Term And Discount Rate	Weighted-average lease term and discount rate were as follows. Three Months Ended March 31, 2024 2023 Cash paid for amounts included in measurement of lease liabilities: Operating cash outflows relating to operating leases $ 117 $ 111 Weighted-average remaining lease term (in years) 3.3 3.2 Weighted-average discount rate 7.28 % 9.29 %

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Accrued Liabilities [Abstract]
Components Of Accrued Liabilities	The following table describes the principal components of accrued liabilities on the Company’s unaudited condensed consolidated balance sheet as of March 31, 2024 and December 31, 2023. March 31, December 31, (in thousands) 2024 2023 Payroll and benefits related expenses $ 1,328 $ 1,189 Collaboration and research agreements expenses 99 217 Professional services 911 951 Other accrued liabilities 459 506 Total accrued liabilities $ 2,797 $ 2,863

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of RSU Activity	The following table summarizes RSU activity for the 2019 Plan during the three months ended March 31, 2024. Options outstanding at December 31, 2023 59,463 RSUs vested and issued ( 16,686 ) Options outstanding at March 31, 2024 42,777 RSUs vested and unissued at March 31, 2024 22,777
Allocation of Non-Cash Stock-Based Compensation Expense By Functional Area	The allocation of non-cash stock-based compensation expense by functional area for the three months ended March 31, 2024 and 2023 was as follows. Three Months Ended March 31, (in thousands) 2024 2023 Cost of revenue $ 18 $ 17 Research and development 66 103 Sales and marketing 25 ( 15 ) General and administrative 253 291 Total $ 362 $ 396
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock Option Activity	The following table summarizes stock option activity for the 2010 Plan during the three months ended March 31, 2024. Options outstanding at December 31, 2023 245,154 Options forfeited or expired ( 33,965 ) Options outstanding at March 31, 2024 211,189
2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock Option Activity	The following table summarizes stock option activity for the 2019 Plan during the three months ended March 31, 2024. Options outstanding at December 31, 2023 514,768 Options granted 140,124 Options forfeited or expired ( 40,805 ) Options outstanding at March 31, 2024 614,087

Loss Per Share (Tables)

Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Loss Per Share [Abstract]
Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share	Three Months Ended March 31, 2024 2023 Numerator: Net Loss $ ( 4,629 ) $ ( 6,578 ) Denominator: Shares used in computing net loss per share, basic and diluted 11,846,075 8,313,091 Net loss per share, basic and diluted $ ( 0.39 ) $ ( 0.79 )

Organization, Basis Of Presen_3

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 3,413,000	$ 7,535,000	$ 2,597,000
Restricted cash	260,000	253,000	258,000
Accumulated deficit	(522,932,000)		$ (518,303,000)
Adjustments to estimates of variable consideration to derecognize revenue	8,000
Working capital	829,000
Net loss	(4,629,000)	(6,578,000)
Net cash used in operating activities	(4,431,000)	(5,706,000)
Receivable impairment	0
Stock-based compensation expense	$ 362,000	$ 396,000
ASU No. 2020-06 [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2024
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
ASU No. 2022-03 [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]	true
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of warrants	$ 1,400,000	$ 1,651,000
Modified Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock called by warrants	366,664
Unmodified Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock called by warrants	433,321
2022 Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of warrants	$ 1,400,000	$ 1,651,000

Fair Value Measurements (Assump

Fair Value Measurements (Assumptions Used to Estimate Fair Value of Warrants) (Details) - 2022 Offering [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Volatility		105.10%
Risk-free interest rate		3.93%
Expected lives (years)		3 years 7 months 20 days
Weighted average fair value		$ 2.064
Unmodified Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Volatility	104.90%
Risk-free interest rate	4.31%
Expected lives (years)	3 years 4 months 20 days
Weighted average fair value	$ 1.329
Modified Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Volatility	101.70%
Risk-free interest rate	4.21%
Expected lives (years)	4 years 9 months 29 days
Weighted average fair value	$ 2.247

Fair Value Measurements (Carryi

Fair Value Measurements (Carrying And Fair Value Of Loan Payable) (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
DECD loan, Carrying value	$ 1,604	$ 1,604
DECD loan, Fair value	$ 1,287	$ 1,255

Prepaid And Other Current Ass_3

Prepaid And Other Current Assets (Schedule Of Prepaid And Other Current Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Prepaid And Other Current Assets [Abstract]
Prepaid insurance	$ 479	$ 684
Software licenses	173	103
Subscriptions	128	26
Other	162	184
Total prepaid and other current assets	$ 942	$ 997

Commitments And Contingencies_2

Commitments And Contingencies (Narrative) (Details)				3 Months Ended		12 Months Ended
	Dec. 03, 2020 USD ($)	Apr. 15, 2016 USD ($)	Mar. 22, 2016 USD ($)	Mar. 31, 2024 USD ($) Item	Mar. 31, 2023 USD ($)	Dec. 31, 2024	Dec. 31, 2023 USD ($)
Commitments And Contingencies [Line Items]
Other income							$ 1,000,000
Amended Loan Agreement [Member]
Commitments And Contingencies [Line Items]
Unamortized debt issuance costs				$ 8,000			$ 8,000
DECD Loan [Member]
Commitments And Contingencies [Line Items]
Proceeds from loan	$ 2,000,000	$ 2,000,000
Maximum loan forgiveness amount under loan agreement			$ 1,500,000
Line of Credit, reduction in principal amount				$ 1,000,000
Percentage of penalty included in loan agreement			5%
Line of credit, maturity date				Jan. 01, 2032
Line of credit, maximum borrowing capacity				$ 4,000,000
Line of credit fixed interest rate			2%
DECD Loan [Member] | Loan Agreement Target Employment Milestone [Member]
Commitments And Contingencies [Line Items]
Proceeds from loan	$ 1,000,000
Insurance Promissory Notes [Member]
Commitments And Contingencies [Line Items]
Debt instrument interest rate							7.79%
Aggregate principal outstanding amount				416,000			$ 670,000
Interest paid				$ 6,000	$ 6,000
Notes payable number of monthly payment installment | Item				9
Notes payable frequency of periodic payment, description				monthly
Insurance Promissory Notes [Member] | Forecast [Member]
Commitments And Contingencies [Line Items]
Maturity date						Oct. 01, 2024

Commitments And Contingencies_3

Commitments And Contingencies (Schedule Of Long-Term Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Commitments And Contingencies [Abstract]
DECD loan, net of issuance costs	$ 1,596	$ 1,596
Less: Current portion, net of issuance costs	(249)	(166)
Total long-term debt, net of issuance costs	$ 1,347	$ 1,430

Commitments And Contingencies_4

Commitments And Contingencies (Annual Amounts Of Future Minimum Principal Payments Due Under Certain Contractual Obligations) (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Debt Instrument [Line Items]
Contractual obligation, 2024	$ 170
Contractual obligation, 2025	335
Contractual obligation, 2026	342
Contractual obligation, 2027	215
Contractual obligation, 2028	129
Contractual obligation, Thereafter	413
Total	1,604
DECD Loan [Member]
Debt Instrument [Line Items]
Contractual obligation, 2024	170
Contractual obligation, 2025	335
Contractual obligation, 2026	342
Contractual obligation, 2027	215
Contractual obligation, 2028	129
Contractual obligation, Thereafter	413
Total	$ 1,604

Commitments And Contingencies_5

Commitments And Contingencies (Operating Leases) (Narrative) (Details)		3 Months Ended
	Oct. 31, 2023 USD ($) Freezer	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	May 30, 2023
Commitments And Contingencies [Line Items]
Fixed lease payment		$ 117,000	$ 111,000
Freezer Storage [Member]
Commitments And Contingencies [Line Items]
Lease renewal term	12 months
Operating lease term	36 months
Lease cost per month	$ 5,200
Number of freezers leased | Freezer	6
Lessee, Operating Lease, Option to Extend	with a twelve-month automatic renewal provision
Austin, Texas Facility [Member]
Commitments And Contingencies [Line Items]
Lease termination date		Feb. 28, 2027
Lease renewal term		37 months
Operating lease term		12 months
Lessee, Operating Lease, Option to Extend		option to extend the lease for an additional three years
Palo Alto, California [Member]
Commitments And Contingencies [Line Items]
Lease termination date		May 31, 2024
Lessee, Operating Lease, Option to Extend		no option for renewal with the sublessor
Shelton, CT [Member]
Commitments And Contingencies [Line Items]
Lease renewal term				5 years
Fixed lease payment		$ 8,900
June 1, 2023 to September 30, 2023 [Member] | Shelton, CT [Member]
Commitments And Contingencies [Line Items]
Reduced fixed lease payment		5,000
October 1, 2024 to September 30, 2027 [Member] | Shelton, CT [Member]
Commitments And Contingencies [Line Items]
Fixed lease payment		5,383
October 1, 2027 to September 30, 2028 [Member] | Shelton, CT [Member]
Commitments And Contingencies [Line Items]
Fixed lease payment		5,768
April 1, 2023 to December 31, 2023 [Member] | Palo Alto, California [Member]
Commitments And Contingencies [Line Items]
Fixed lease payment		9,000
January 1, 2024 to May 31, 2024 [Member] | Palo Alto, California [Member]
Commitments And Contingencies [Line Items]
Fixed lease payment		10,000
July 1, 2023 to January 31, 2024 [Member] | Austin, Texas Facility [Member]
Commitments And Contingencies [Line Items]
Fixed lease payment		9,490
February 1, 2024 to January 31, 2025, Except August 2024 [Member] | Austin, Texas Facility [Member]
Commitments And Contingencies [Line Items]
Fixed lease payment		7,100
August 2024 [Member] | Austin, Texas Facility [Member]
Commitments And Contingencies [Line Items]
Fixed lease payment		0
February 1, 2025 to January 31, 2026 [Member] | Austin, Texas Facility [Member]
Commitments And Contingencies [Line Items]
Fixed lease payment		8,600
February 1, 2026 to January 31, 2027 [Member] | Austin, Texas Facility [Member]
Commitments And Contingencies [Line Items]
Fixed lease payment		8,900
February 2027 [Member] | Austin, Texas Facility [Member]
Commitments And Contingencies [Line Items]
Fixed lease payment		$ 9,100

Commitments And Contingencies_6

Commitments And Contingencies (Expense Associated With Operating Leases) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cost Of Revenue [Member]
Lessee, Lease, Description [Line Items]
Operating rent expense	$ 41	$ 24
Variable rent expense	5	15
Research And Development [Member]
Lessee, Lease, Description [Line Items]
Operating rent expense	17	6
Variable rent expense	0	3
Sales And Marketing [Member]
Lessee, Lease, Description [Line Items]
Operating rent expense	1	2
Variable rent expense	2	2
General And Administrative [Member]
Lessee, Lease, Description [Line Items]
Operating rent expense	10	21
Variable rent expense	$ 9	$ 21

Commitments And Contingencies_7

Commitments And Contingencies (Future Lease Payments Related To Operating Leases) (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Commitments And Contingencies [Abstract]
2024	$ 172
2025	229
2026	223
2027	84
2028	52
Total Operating Lease Payments	760
Less: Imputed Interest	(85)
Present Value of Lease Liabilities	675
Less: Operating Lease Liability, current portion	(188)	$ (159)
Operating Lease Liability, non-current portion	$ 487	$ 427

Commitments And Contingencies_8

Commitments And Contingencies (Summary Of Weighted-Average Lease Term And Discount Rate) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Commitments And Contingencies [Abstract]
Operating cash outflows relating to operating leases	$ 117	$ 111
Weighted-average remaining lease term (in years)	3 years 3 months 18 days	3 years 2 months 12 days
Weighted-average discount rate	7.28%	9.29%

Commitments And Contingencies_9

Commitments And Contingencies (Non-Cancellable Royalty Obligations And Business Agreements) (Narrative) (Details) - USD ($)		3 Months Ended				6 Months Ended	12 Months Ended	20 Months Ended
	Aug. 08, 2022	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2024	Mar. 20, 2024	Mar. 31, 2024
Commitments And Contingencies [Line Items]
Royalty expense		$ 72,000		$ 90,000
Research and development		$ 906,000		1,267,000
Research Collaboration Agreement With Johns Hopkins University School Of Medicine [Member]
Commitments And Contingencies [Line Items]
Percent of royalty paid		4%
Royalty payments		$ 57,500
Sponsored Research Agreement With Multiple Entities [Member]
Commitments And Contingencies [Line Items]
Agreement amount	$ 1,252,000
Agreement amount, percent paid or payable					68%
Research and development		34,000		$ 23,000				$ 1,117,000
License Agreement With Multiple Entities [Member]
Commitments And Contingencies [Line Items]
Initial license fee		75,000
Annual license fee		50,000					$ 50,000
Forecast [Member] | Sponsored Research Agreement With Multiple Entities [Member]
Commitments And Contingencies [Line Items]
Agreement amount, percent paid or payable						17%
Completion of certain deliverables, first [Member] | Sponsored Research Agreement With Multiple Entities [Member]
Commitments And Contingencies [Line Items]
Agreement amount, percent paid or payable			15%
Maximum [Member] | License Agreement With Multiple Entities [Member]
Commitments And Contingencies [Line Items]
Royalty expense		$ 1,350,000

Accrued Liabilities (Components

Accrued Liabilities (Components Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accrued Liabilities [Abstract]
Payroll and benefits related expenses	$ 1,328	$ 1,189
Collaboration and research agreements expenses	99	217
Professional services	911	951
Other accrued liabilities	459	506
Total accrued liabilities	$ 2,797	$ 2,863

Stockholders' Deficit (Narrativ

Stockholders' Deficit (Narrative) (Details) - USD ($)									3 Months Ended		12 Months Ended		14 Months Ended
	May 13, 2024	May 10, 2024	Feb. 26, 2024	Jan. 24, 2024	Jul. 20, 2023	May 09, 2023	Mar. 28, 2023	Feb. 10, 2023	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2024	Apr. 25, 2024	Jan. 26, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized									200,000,000		200,000,000	150,000,000	200,000,000
Common stock, par value									$ 0.001		$ 0.001	$ 0.001	$ 0.001
Change in fair value of warrant liabilities									$ (251,000)	$ 24,000
2022 Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Change in fair value of warrant liabilities									$ 106,000
Shares of common stock called by warrants												366,664
Exercise price of warrants															$ 13.2
2022 Amended Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reduction in exercise price									$ 4.13
Change in fair value of warrant liabilities									$ 490,000
Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value				$ 0.001	$ 0.001
Payment of stock issuance expenses				$ 694,000	$ 597,000
Common stock shares issued				1,371,000	1,694,820
Proceeds from public offering				$ 5,563,000	$ 4,700,000
Issuance costs				$ 694,000	$ 597,000
Shares issued price per share deduction				$ 0.0001
Purchase Agreement [Member] | Directors And Executive Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued					44,347
Share Price					$ 3.98
Purchase Agreement [Member] | Investors [Members]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued				1,368,600	1,650,473
Share Price				$ 3.5	$ 2.75
Purchase Agreement [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued				2,400
Stock price per share				$ 4.2555
Purchase Agreement [Member] | Pre-Funded Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock called by warrants				200,000
Gross proceeds warrants exercised			$ 20
Exercise price of warrants				$ 0.0001
Warrant restriction, threshold common stock held, percent				9.99%
Purchase Agreement [Member] | Purchase Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price				$ 0.125
Shares of common stock called by warrants				1,571,000
Exercise price of warrants				$ 4.13
Warrant term				5 years
Placement Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value								$ 0.001
Maximum aggregate offering price								$ 12,500,000
Payment of stock issuance expenses									$ 0
Common stock shares issued									0				35,552
Proceeds from public offering													$ 211,000
Issuance costs									$ 0
Stock issuance expenses, net equity impact									134,000
Purchase Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum aggregate offering price							$ 10,000,000
LPC Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value							$ 0.001
Stock issuance expenses									$ 326,000
Common stock shares issued									111,369		472,312
Proceeds from public offering									$ 400,000		$ 1,578,000
Purchase agreement term							36 months
Maximum number of shares per purchase							6,667
Stock issued for services									258,000
Legal expenses									40,000	$ 0		$ 38,000
Lincoln Park Capital Fund [Member] | LPC Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued											47,733
Stock transaction costs									$ 30,000
Alliance Global Partners [Member] | Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Placement agent cash fee paid				7%	7%
Non-accountable expense allowance				$ 30,000	$ 30,000
Legal expenses				$ 75,000	$ 75,000
Placement agent cash fee				3.50%
Alliance Global Partners [Member] | Purchase Agreement [Member] | Directors And Executive Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Placement agent cash fee paid					3.50%
Alliance Global Partners [Member] | Purchase Agreement [Member] | Investors [Members]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued					182,447
Not below $7.50 [Member] | LPC Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price							$ 7.5
Maximum number of shares per purchase							13,333
Not below $11.25 [Member] | LPC Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price							$ 11.25
Maximum number of shares per purchase							16,666
Not below $15.00 [Member] | LPC Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price							$ 15
Maximum number of shares per purchase							20,000
Subsequent Event [Member] | LPC Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued		100,408
Proceeds from public offering		$ 300,000
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance									0		0		0
Share based compensation, options outstanding									211,189		211,189	245,154	211,189
Weighted average exercise price of outstanding									$ 24.05		$ 24.05		$ 24.05
Weighted average remaining life									8 months 12 days
2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance									66,542		66,542		66,542
Share based compensation shares authorized for grants									699,485		699,485		699,485
Additional shares authorized						333,333
Share based compensation, options outstanding									614,087		614,087	514,768	614,087
Share based compensation, nonvested restricted shares									42,777		42,777	59,463	42,777
Interest rate, minimum									4.33%
Interest rate, maximum									4.56%
Forfeitures amount									$ 12,000
Weighted average exercise price of outstanding									$ 11.77		$ 11.77		$ 11.77
Weighted average remaining life									1 year 11 months 1 day
Weighted average grant date fair value									$ 2.97
Weighted average exercise price									4.77
2019 Stock Incentive Plan [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares authorized for grants	2,032,818
Additional shares authorized	1,000,000
Minimum [Member] | 2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price									$ 4		4		4
Expected term									2 years
Maximum [Member] | LPC Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum amount per purchase							$ 1,000,000
Maximum [Member] | Subsequent Event [Member] | Lincoln Park Capital Fund [Member] | Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining number of shares to be sold under the agreement														8,422,000
Maximum [Member] | 2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price									$ 4.87		$ 4.87		$ 4.87
Expected term									3 years
Common Stock [Member] | Purchase Agreement [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price				$ 4.13
Unvested Stock Option Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs related to nonvested stock option awards									$ 696,000		$ 696,000		$ 696,000
Weighted average period over which unrecognized cost expected to be recognized									1 year 11 months 1 day
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs related to nonvested stock option awards									$ 52,000		$ 52,000		$ 52,000
Weighted average period over which unrecognized cost expected to be recognized									3 months

Stockholders' Deficit (Summary

Stockholders' Deficit (Summary Of Stock Option Activity) (Details)	3 Months Ended
	Mar. 31, 2024 shares
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding	245,154
Options forfeited or expired	(33,965)
Options outstanding	211,189
2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding	514,768
Options granted	140,124
Options forfeited or expired	(40,805)
Options outstanding	614,087

Stockholders' Deficit (Summar_2

Stockholders' Deficit (Summary of RSU Activity) (Details) - 2019 Stock Incentive Plan [Member]	3 Months Ended
	Mar. 31, 2024 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
RSUs outstanding	59,463
RSUs vested and issued	(16,686)
RSUs outstanding	42,777
RSUs vested and unissued	22,777

Stockholders' Deficit (Allocati

Stockholders' Deficit (Allocation of Non-Cash Stock-Based Compensation Expense By Functional Area) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 362	$ 396
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	18	17
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	66	103
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	25	(15)
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 253	$ 291

Loss Per Share (Narrative) (Det

Loss Per Share (Narrative) (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Potential Shares Of Aspira Common Stock [Member]
Antidilutive securities excluded from computation of earnings per share	3,239,038	1,583,982
Warrant [Member]
Antidilutive securities excluded from computation of earnings per share	2,370,985	799,985

Loss Per Share (Reconciliation

Loss Per Share (Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Loss (Numerator)
Net loss	$ (4,629,000)	$ (6,578,000)
Shares (Denominator)
Shares used in computing net loss per share, basic	11,846,075	8,313,091
Shares used in computing net loss per share, diluted	11,846,075	8,313,091
Per Share Amount
Net loss per share - basic	$ (0.39)	$ (0.79)
Net loss per share - diluted	$ (0.39)	$ (0.79)